N
NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES
NASDAQ: NAMS (NewAmsterdam Pharma Company N.V)
最近更新时间: 6小时之前36.76
-0.29 (-0.78%)
| 前收盘价格 | 37.05 |
| 收盘价格 | 36.47 |
| 成交量 | 879,249 |
| 平均成交量 (3个月) | 1,050,685 |
| 市值 | 4,168,245,504 |
| 价格/销量 (P/S) | 51.43 |
| 股市价格/股市净资产 (P/B) | 4.44 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2025 |
| 营业利益率 (TTM) | -2,314.47% |
| 稀释每股收益 (EPS TTM) | -1.84 |
| 季度收入增长率 (YOY) | 112.60% |
| 总债务/股东权益 (D/E MRQ) | 0.05% |
| 流动比率 (MRQ) | 19.98 |
| 营业现金流 (OCF TTM) | -140.43 M |
| 杠杆自由现金流 (LFCF TTM) | -99.00 M |
| 资产报酬率 (ROA TTM) | -18.15% |
| 股东权益报酬率 (ROE TTM) | -31.51% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | NewAmsterdam Pharma Company N.V | 看涨 | 看涨 |
AIStockmoo 评分
1.4
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.38 |
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.39% |
| 机构持股比例 | 111.32% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 30 Jun 2025 | 16,607,074 |
| Bain Capital Life Sciences Investors, Llc | 30 Jun 2025 | 10,719,110 |
| Fcpm Iii Services B.V. | 30 Jun 2025 | 10,632,113 |
| Ra Capital Management, L.P. | 30 Jun 2025 | 10,138,938 |
| Capital World Investors | 30 Jun 2025 | 8,387,725 |
| Viking Global Investors Lp | 30 Jun 2025 | 6,978,534 |
| Deerfield Management Company, L.P. | 30 Jun 2025 | 5,115,953 |
| Adage Capital Partners Gp, L.L.C. | 30 Jun 2025 | 3,013,009 |
| Medicxi Ventures Management (Jersey) Ltd | 30 Sep 2025 | 2,869,565 |
| Polar Capital Holdings Plc | 30 Jun 2025 | 2,517,779 |
| Cormorant Asset Management, Lp | 30 Jun 2025 | 2,175,000 |
| Capital International Investors | 30 Jun 2025 | 2,062,535 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 52.00 (HC Wainwright & Co., 41.46%) | 购买 |
| 中 | 46.00 (25.14%) | |
| 低 | 44.00 (RBC Capital, 19.70%) | 购买 |
| 平均值 | 47.40 (28.95%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 34.79 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| RBC Capital | 06 Nov 2025 | 44.00 (19.70%) | 购买 | 37.05 |
| Needham | 05 Nov 2025 | 46.00 (25.14%) | 购买 | 38.13 |
| HC Wainwright & Co. | 20 Oct 2025 | 52.00 (41.46%) | 购买 | 37.66 |
| Citigroup | 17 Oct 2025 | 50.00 (36.02%) | 购买 | 36.40 |
| Wells Fargo | 25 Aug 2025 | 45.00 (22.42%) | 购买 | 24.70 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合